CDK9-IN-22_product_DataBase

Bioactivity	CDK9-IN-22 is a potent CDK9 inhibitor with IC50s of 10.4, 876.2 nM for CDK9, CDK, respectively. CDK9-IN-22 induces apoptosis and cell cycle arrests at G2/M phase. CDK9-IN-22 decreases the expression of p-RNAPII (S2) and CDK9 protein. CDK9-IN-22 shows antiproliferative and aiti-tumor activity[1].
Invitro	CDK9-IN-22 (compound 8 d) (0.1, 0.5, 2.5 µM; 24, 48 h) 在 PANC-1 细胞中以浓度依赖性方式诱导细胞凋亡和细胞周期停滞在 G2/M 期[1 ].CDK9-IN-22 (0.1, 0.5, 2.5 µM; 24 h) 降低 PANC-1 细胞中 p-RNAPII (S2) 和 CDK9 蛋白的表达[1]。 Cell Proliferation Assay[1] Cell Line:
In Vivo	CDK9-IN-22 (5, 10, 20 mg/kg; i.p.; every other day for four weeks) 抑制异种移植小鼠模型中的肿瘤生长[1]。 Animal Model:
Name	CDK9-IN-22
CAS	2872677-61-5
Formula	C28H28FN5O2
Molar Mass	485.55
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Xu Z, et al. Design, synthesis and anticancer evaluation of selective 2,4-disubstituted pyrimidine CDK9 inhibitors. Eur J Med Chem. 2022 Dec 15;244:114875.

PeptideDB